Literature DB >> 21153681

Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: implications for chemotherapy.

Shailendra Joshi1, Aysegul Ergin, Mei Wang, Roberto Reif, Jane Zhang, Jeffrey N Bruce, Irving J Bigio.   

Abstract

The novel ability to quantify drug and tracer concentrations in vivo by optical means leads to the possibility of detecting and quantifying blood brain barrier (BBB) disruption in real-time by monitoring concentrations of chromophores such as Evan's Blue. In this study, experiments were conducted to assess the disruption of the BBB, by intraarterial injection of mannitol, in New Zealand white rabbits. Surgical preparation included: tracheotomy for mechanical ventilation, femoral and selective internal carotid artery (ICA) catheterizations, skull screws for monitoring electrocerebral activity, bilateral placement of laser Doppler probes and a small craniotomy for the placement of a fiber optic probe to determine tissue Evan's Blue dye concentrations. Evans Blue (6.5 mg/kg) was injected intravenously (IV) just before BBB disruption with intracarotid mannitol (25%, 8 ml/40 s). Brain tissue concentrations of the dye in mannitol-treated and control animals were monitored using the method of optical pharmacokinetics (OP) during the subsequent 60 min. Hemodynamic parameters, heart rate, blood pressure, and EKG remained stable throughout the experiments in both the control and the mannitol-treated group. Brain tissue concentrations of Evan's Blue and the brain:plasma Evan's Blue partition coefficient progressively increased during the period of observation. A wide variation in brain tissue Evan's Blue concentrations was observed in the mannitol group. The experiments demonstrate the feasibility of measuring tissue concentrations of Evan's Blue without invading the brain parenchyma, and in real-time. The data suggest that there are significant variations in the degree and duration of BBB disruption induced with intraarterial mannitol. The ability to optically monitor the BBB disruption in real-time could provide a feedback control for hypertonic disruption and/or facilitate dosage control for chemotherapeutic drugs that require such disruption.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21153681      PMCID: PMC4013427          DOI: 10.1007/s11060-010-0466-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  49 in total

1.  Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.

Authors:  E Zylber-Katz; J M Gomori; A Schwartz; A Lossos; F Bokstein; T Siegal
Journal:  Clin Pharmacol Ther       Date:  2000-06       Impact factor: 6.875

2.  Quantitative analysis of papaverine-mediated blood-brain barrier disruption in rats.

Authors:  A K Bhattacharjee; T Kondoh; T Nagashima; M Ikeda; K Ehara; N Tamaki
Journal:  Biochem Biophys Res Commun       Date:  2001-11-30       Impact factor: 3.575

3.  Effects of mild hypothermia on blood-brain barrier disruption during isoflurane or pentobarbital anesthesia.

Authors:  O Z Chi; X Liu; H R Weiss
Journal:  Anesthesiology       Date:  2001-10       Impact factor: 7.892

4.  Optison (FS069) disrupts the blood-brain barrier in rats.

Authors:  G Mychaskiw; A E Badr; R Tibbs; B R Clower; J H Zhang
Journal:  Anesth Analg       Date:  2000-10       Impact factor: 5.108

5.  The effects of the Na(+)/Ca(++) exchange blocker on osmotic blood-brain barrier disruption.

Authors:  A K Bhattacharjee; T Nagashima; T Kondoh; N Tamaki
Journal:  Brain Res       Date:  2001-05-11       Impact factor: 3.252

6.  Blood-brain barrier disruption following the internal carotid arterial perfusion of alkyl glycerols.

Authors:  Hwa Jeong Lee; Yun Zhang; William M Pardridge
Journal:  J Drug Target       Date:  2002-09       Impact factor: 5.121

7.  Electrocerebral silence by intracarotid anesthetics does not affect early hyperemia after transient cerebral ischemia in rabbits.

Authors:  Shailendra Joshi; Mei Wang; Ervant V Nishanian; Ronald G Emerson
Journal:  Anesth Analg       Date:  2004-05       Impact factor: 5.108

Review 8.  The blood-brain barrier: an overview: structure, regulation, and clinical implications.

Authors:  Praveen Ballabh; Alex Braun; Maiken Nedergaard
Journal:  Neurobiol Dis       Date:  2004-06       Impact factor: 5.996

9.  Retinal discoloration test.

Authors:  Shailendra Joshi; Mei Wang; Roger Hartl
Journal:  J Cereb Blood Flow Metab       Date:  2004-03       Impact factor: 6.200

Review 10.  Calcium modulation of adherens and tight junction function: a potential mechanism for blood-brain barrier disruption after stroke.

Authors:  Rachel C Brown; Thomas P Davis
Journal:  Stroke       Date:  2002-06       Impact factor: 7.914

View more
  23 in total

1.  Gene Silencing in the Right Place at the Right Time.

Authors:  Anna Gutkin; Dan Peer
Journal:  Mol Ther       Date:  2018-10-23       Impact factor: 11.454

2.  Impact of drug size on brain tumor and brain parenchyma delivery after a blood-brain barrier disruption.

Authors:  Marie Blanchette; Luc Tremblay; Martin Lepage; David Fortin
Journal:  J Cereb Blood Flow Metab       Date:  2014-02-12       Impact factor: 6.200

3.  Paradoxical increase in the bispectral index during deep anesthesia in New Zealand white rabbits.

Authors:  Alexander Romanov; Rajinder-Singh Moon; Mei Wang; Shailendra Joshi
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-01       Impact factor: 1.232

4.  Real-time hemodynamic response and mitochondrial function changes with intracarotid mannitol injection.

Authors:  Shailendra Joshi; Rajinder Singh-Moon; Mei Wang; Jeffrey N Bruce; Irving J Bigio; Avraham Mayevsky
Journal:  Brain Res       Date:  2014-01-15       Impact factor: 3.252

5.  Noninvasive in vivo optical assessment of blood brain barrier permeability and brain tissue drug deposition in rabbits.

Authors:  Aysegul Ergin; Mei Wang; Jane Zhang; Irving Bigio; Shailendra Joshi
Journal:  J Biomed Opt       Date:  2012-05       Impact factor: 3.170

Review 6.  Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma.

Authors:  Aniket S Wadajkar; Jimena G Dancy; David S Hersh; Pavlos Anastasiadis; Nhan L Tran; Graeme F Woodworth; Jeffrey A Winkles; Anthony J Kim
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-11-04

7.  Intra-arterial delivery of AAV vectors to the mouse brain after mannitol mediated blood brain barrier disruption.

Authors:  Conor P Foley; David G Rubin; Alejandro Santillan; Dolan Sondhi; Jonathan P Dyke; Ronald G Crystal; Y Pierre Gobin; Douglas J Ballon
Journal:  J Control Release       Date:  2014-09-28       Impact factor: 9.776

8.  Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound.

Authors:  Jessica F Jordão; Emmanuel Thévenot; Kelly Markham-Coultes; Tiffany Scarcelli; Ying-Qi Weng; Kristiana Xhima; Meaghan O'Reilly; Yuexi Huang; Joanne McLaurin; Kullervo Hynynen; Isabelle Aubert
Journal:  Exp Neurol       Date:  2013-05-21       Impact factor: 5.330

Review 9.  Which drug or drug delivery system can change clinical practice for brain tumor therapy?

Authors:  Tali Siegal
Journal:  Neuro Oncol       Date:  2013-03-15       Impact factor: 12.300

Review 10.  Therapeutic nanomedicine for brain cancer.

Authors:  Stephany Y Tzeng; Jordan J Green
Journal:  Ther Deliv       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.